SUPPLEMENT

Q4 2025 — Investor materials

Q4 2025PDF · 5 pages585 KB
December 17, 2025
2025 Q4 Economic Factors and J&J Announcements
Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well
as public commentary made by management during the quarter and recent earnings calls. Any additional information
included herein is provided as phasing considerations and should not be construed as guidance.
Phasing considerations:
In addition to the comments provided during the Q3 earnings call, please note the following:
• 	As a reminder, MSD return of rights for SIMPONI/SIMPONI ARIA and REMICADE occurred in the fourth
quarter of 2024.
• 	For your convenience, as we close 2025, we have attached QTD and FY segment P&Ls for 2024.
Macro-economic factors:
• 	Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as
well as interest income on our cash position.
• 	Tariffs: in Q2 we noted a 2025 expected impact of $200M, exclusively related to our MedTech business,
based on tariff information known at that time. We continue to monitor tariffs and their potential impact to
our business.
• 	Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to
experience, impacts to the Company's business resulting from the Russia-Ukraine war, rising conflict in the
Middle East as well as increasing tensions between the U.S. and China.
• 	Foreign Exchange: We don’t offer guidance or predictions on currency movements, but as highlighted by Joe
during the Q3 2025 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar as of mid-October
of 1.17 to give a sense of the potential impact on Full Year 2025 guidance. The Euro Spot Rate averaged 1.16 in
October, 1.16 in November, and 1.16 through mid-December. As a reminder, our results are based on a basket of
currencies, of which, not all align to the Euro.
Conference participation
J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for
the events below have been attached for your convenience.
• 	Guggenheim 2 nd Annual Healthcare Innovation Conference: Sarah Brennan – Chairman, Global Commercial
Strategy Organization and Mark Wildgust - Vice President, Global Medical Affairs, Oncology, fireside chat
with Vamil Divan - Guggenheim Securities LLC, Analyst
• 	UBS Global Healthcare Conference: Peter Menziuso – Company Group Chairman, Vision, fireside chat with
Danielle Antalffy – UBS AG, Analyst
• 	7 th Annual Wolfe Research Healthcare Conference: Candice Long – Worldwide Vice President – Immunology,
Global Strategic Commercial Organization, and David Lee- Senior Vice President, Global Immunology
Therapeutic Area Head, fireside chat with Alexandria Hammond – Wolfe Research LLC, Equity Analyst
• 	Citi 2025 Global Healthcare Conference: Michael Bodner –Group Chair of Electrophysiology and
Neurovascular, fireside chat with Joanne Wuensch – Citi, Analyst

-- 1 of 5 --

Announcements
Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom,
and MedTech News & Events page.
• 	M&A: Acquisition of Halda Therapeutics
o 	Under the terms of the agreement, Johnson & Johnson will acquire Halda. The transaction will be
accounted for as a business combination and is expected to close within the next few months,
subject to antitrust clearance and other customary closing conditions. The Company expects
dilution in 2026 of $0.15 to Adjusted Earnings Per Share (EPS) due to short-term financing and a
non-recurring charge related to the equity awards for Halda employees upon closing. Further
commentary on full year 2026 guidance will be provided during the fourth quarter earnings call.
• 	Talc: please visit factsabouttalc.com for the latest company statements
• 	Innovative Medicine:
o 	CARVYKTI: CARTITUDE-4 follow-up data
o 	CAPLYTA: FDA approval
o 	DARZALEX: Phase 3 AQUILA data
o 	Icotrokinra: Phase 2b ANTHEM-UC data; Phase 3 ICONIC-TOTAL data
o 	IMAAVY: EPIC study and Vibrance-MG data
o 	INLEXZO: Cohort 4 SunRISe-1 data
o 	Nipocalimab: Phase 2 DAHLIAS data
o 	Psoriasis: ENCOMPASS study
o 	RYBREVANT: Phase 1b/2 OrigAMI-4
o 	TECVAYLI & DARZALEX FASPRO: Phase 3 MajesTEC-3 data; Phase 3 MajesTEC-3 topline results
o 	TREMFYA: Phase 3b APEX data; Phase 3 GRAVITI and GALAXI data
• 	MedTech:
o 	Shockwave: Disrupt BTK II data
o 	VARIPULSE: APHRS and JPHRS data presentations

-- 2 of 5 --

J&J earnings calls:
• 	Q3 2025 earnings call: Full year 2025 Operational Sales Guidance excluding the COVID-19 Vaccine of
$93.0B - $93.4B or 4.8% - 5.3% and Adjusted Operational Earnings Per Share of $10.63 -
$10.73 or 6.5% - 7.5% was provided on our Q3 2025 Earnings Call. Please see the below 2026 Considerations
slide from the earnings presentation. For your convenience, the final Q3 2025 earnings transcript and
presentation are attached. Full Q3 2025 earnings call operational commentary and key drivers can be
listened to here and the Q3 2025 10-Q can be found here.
• 	Q4 2024 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth
rates for Q4 2024. Full Q4 2024 operational commentary, key drivers, and one-timers can be listened
to here and the Q4 2024 10-K can be found here. For your convenience, the final Q4 2024 earnings
transcript and presentation are attached.
Q4 2024:
o 	Enterprise: $22.5B, 6.7% operational sales growth and 5.7% adjusted operational sales growth
 	Enterprise sales highlights can be found on page 5 of the final Q4 2024 earnings transcript attached
 	P&L highlights can be found on page 6 of the final Q4 2024 earnings transcript attached
o 	Innovative Medicine: $14.3B, 6.1% operational sales growth
 	Innovative Medicine sales highlights can be found on page 5 of the final Q4 2024 earnings transcript
attached
o 	MedTech: $8.2B, 7.6% operational sales growth
 	MedTech sales highlights can be found on page 6 of the final Q4 2024 earnings transcript attached

-- 3 of 5 --



-- 4 of 5 --



-- 5 of 5 --